{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T18:11:00Z","timestamp":1785607860049,"version":"3.56.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"NSFC","doi-asserted-by":"crossref","award":["82003872"],"award-info":[{"award-number":["82003872"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2022JJ50163"],"award-info":[{"award-number":["2022JJ50163"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2023JJ20034"],"award-info":[{"award-number":["2023JJ20034"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hunan Provincial Health High-Level Talent Scientific Research Project","award":["R2023074"],"award-info":[{"award-number":["R2023074"]}]},{"name":"Hunan Province Clinical Medical Technology Innovation Guidance Project","award":["2020SK51823"],"award-info":[{"award-number":["2020SK51823"]}]},{"name":"Hunan Province Clinical Medical Technology Innovation Guidance Project","award":["2021SK51828"],"award-info":[{"award-number":["2021SK51828"]}]},{"name":"Hunan Province Clinical Medical Technology Innovation Guidance Project","award":["2021SK51823"],"award-info":[{"award-number":["2021SK51823"]}]},{"name":"Hunan Provincial Clinical Medical Research Center for Drug Evaluation of major chronic diseases\u00a0","award":["2023SK4040"],"award-info":[{"award-number":["2023SK4040"]}]},{"name":"The science and technology innovation Program of Hunan Province","award":["2023RC3173"],"award-info":[{"award-number":["2023RC3173"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10557-024-07653-2","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T04:24:58Z","timestamp":1733286298000},"page":"1309-1319","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Investigating Sodium-Glucose Cotransporter 2 Inhibitors Versus Other Glucose-Lowering Drugs on Ventricular Arrhythmias or Sudden Cardiac Death Using the US FDA Adverse Event Reporting System"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0594-9103","authenticated-orcid":false,"given":"Bo","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4923-5142","authenticated-orcid":false,"given":"Tianqiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongwen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoqian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jixiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zunbo","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3037-3997","authenticated-orcid":false,"given":"Jiecan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"issue":"10365","key":"7653_CR1","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/S0140-6736(22)01655-5","volume":"400","author":"E Ahmad","year":"2022","unstructured":"Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ. Type 2 diabetes. Lancet. 2022;400(10365):1803\u201320.","journal-title":"Lancet"},{"key":"7653_CR2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","volume":"83","author":"V Vallon","year":"2021","unstructured":"Vallon V, Verma S. Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annu Rev Physiol. 2021;83:503\u201328.","journal-title":"Annu Rev Physiol"},{"key":"7653_CR3","doi-asserted-by":"crossref","unstructured":"K\u00f6nemann H, Dagres N, Merino JL, et al. Spotlight on the 2022 ESC guideline management of ventricular arrhythmias and prevention of sudden cardiac death: 10 novel key aspects. Europace. 2023;25(5):euad091.","DOI":"10.1093\/europace\/euad091"},{"issue":"4","key":"7653_CR4","first-page":"418","volume":"38","author":"CA Remme","year":"2022","unstructured":"Remme CA. Sudden cardiac death in diabetes and obesity: mechanisms and therapeutic strategies. Can J Cardiol. 2022;38(4):418\u201326.","journal-title":"Can J Cardiol"},{"issue":"28","key":"7653_CR5","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1093\/eurheartj\/ehz891","volume":"41","author":"TH Lynge","year":"2020","unstructured":"Lynge TH, Svane J, Pedersen-Bjergaard U, et al. Sudden cardiac death among persons with diabetes aged 1\u201349 years: a 10-year nationwide study of 14 294 deaths in Denmark. Eur Heart J. 2020;41(28):2699\u2013706.","journal-title":"Eur Heart J"},{"issue":"8","key":"7653_CR6","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/ndt\/gfz232","volume":"36","author":"LC Pickup","year":"2021","unstructured":"Pickup LC, Law JP, Townend JN, Ferro CJ. Sudden cardiac death in chronic renal disease: aetiology and risk reduction strategies. Nephrol Dial Transplant. 2021;36(8):1386\u20138.","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"7653_CR7","doi-asserted-by":"publisher","first-page":"e722","DOI":"10.1161\/CIR.0000000000001040","volume":"145","author":"JJ Joseph","year":"2022","unstructured":"Joseph JJ, Deedwania P, Acharya T, et al. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association. Circulation. 2022;145(9):e722\u201359.","journal-title":"Circulation"},{"issue":"9852","key":"7653_CR8","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1016\/S0140-6736(12)61413-5","volume":"380","author":"RM John","year":"2012","unstructured":"John RM, Tedrow UB, Koplan BA, et al. Ventricular arrhythmias and sudden cardiac death. Lancet. 2012;380(9852):1520\u20139.","journal-title":"Lancet"},{"issue":"1","key":"7653_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12933-020-01127-z","volume":"19","author":"W Shimizu","year":"2020","unstructured":"Shimizu W, Kubota Y, Hoshika Y, et al. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. Cardiovasc Diabetol. 2020;19(1):148.","journal-title":"Cardiovasc Diabetol"},{"issue":"17","key":"7653_CR10","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1093\/eurjpc\/zwab173","volume":"28","author":"N Zhang","year":"2022","unstructured":"Zhang N, Wang Y, Tse G, et al. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022;28(17):1961\u201373.","journal-title":"Eur J Prev Cardiol"},{"issue":"22","key":"7653_CR11","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"4","key":"7653_CR12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"key":"7653_CR13","unstructured":"Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788\u20131801."},{"issue":"36","key":"7653_CR14","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1093\/eurheartj\/ehab560","volume":"42","author":"JP Curtain","year":"2021","unstructured":"Curtain JP, Docherty KF, Jhund PS, et al. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J. 2021;42(36):3727\u201338.","journal-title":"Eur Heart J"},{"issue":"1","key":"7653_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/europace\/euab177","volume":"24","author":"D Sfairopoulos","year":"2022","unstructured":"Sfairopoulos D, Zhang N, Wang Y, et al. Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials. Europace. 2022;24(1):20\u201330.","journal-title":"Europace"},{"issue":"7","key":"7653_CR16","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.hrthm.2021.03.028","volume":"18","author":"GC Fernandes","year":"2021","unstructured":"Fernandes GC, Fernandes A, Cardoso R, et al. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials. Heart Rhythm. 2021;18(7):1098\u2013105.","journal-title":"Heart Rhythm"},{"issue":"1","key":"7653_CR17","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12933-021-01293-8","volume":"20","author":"HL Li","year":"2021","unstructured":"Li HL, Lip GYH, Feng Q, et al. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis. Cardiovasc Diabetol. 2021;20(1):100.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"7653_CR18","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/dom.14854","volume":"25","author":"AM Fawzy","year":"2023","unstructured":"Fawzy AM, Rivera-Caravaca JM, Underhill P, Fauchier L, Lip GYH. Incident heart failure, arrhythmias and cardiovascular outcomes with sodium-glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: insights from a global federated electronic medical record database. Diabetes Obes Metab. 2023;25(2):602\u201310.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"7653_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12933-021-01243-4","volume":"20","author":"BM Bonora","year":"2021","unstructured":"Bonora BM, Raschi E, Avogaro A, Fadini GP. SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system. Cardiovasc Diabetol. 2021;20(1):39.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"7653_CR20","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1080\/14740338.2023.2216453","volume":"23","author":"L Zhang","year":"2024","unstructured":"Zhang L, Pan C, Yang X, Jiang D, Cao M. Sodium-glucose cotransporter-2 inhibitors and cardiovascular safety profile: a pharmacovigilance analysis of the US food and drug administration adverse event reporting system. Expert Opin Drug Saf. 2024;23(6):785\u201392.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"7653_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12933-023-01743-5","volume":"22","author":"A Goldman","year":"2023","unstructured":"Goldman A, Fishman B, Twig G, et al. The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (\u2265 75 years): a retrospective, pharmacovigilance study. Cardiovasc Diabetol. 2023;22(1):16.","journal-title":"Cardiovasc Diabetol"},{"key":"7653_CR22","unstructured":"U.S. Food and Drug Administration. Questions and answers on FDA\u2019s Adverse Event Reporting System (FAERS). https:\/\/www.fda.gov\/drugs\/surveillance\/questions-and-answers-fdas-adverse-event-reporting-system-faers. Accessed 30 Jan 2024"},{"issue":"7","key":"7653_CR23","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nbt.3623","volume":"34","author":"M Sarangdhar","year":"2016","unstructured":"Sarangdhar M, Tabar S, Schmidt C, et al. Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data. Nat Biotechnol. 2016;34(7):697\u2013700.","journal-title":"Nat Biotechnol"},{"key":"7653_CR24","unstructured":"WHO collaborating centre for drug statistics methodology. ATC\/DDD Index 2024. https:\/\/www.whocc.no\/atc_ddd_index\/. Accessed 30 Jan 2024."},{"issue":"9","key":"7653_CR25","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S2213-8587(17)30257-7","volume":"5","author":"GP Fadini","year":"2017","unstructured":"Fadini GP, Avogaro A. SGLT2 inhibitors and amputations in the US FDA adverse event reporting system. Lancet Diabetes Endocrinol. 2017;5(9):680\u20131.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"7653_CR26","doi-asserted-by":"crossref","unstructured":"Noguchi Y, Tachi T, Teramachi H. Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source.\u00a0Brief Bioinform. 2021;22(6):bbab347.","DOI":"10.1093\/bib\/bbab347"},{"issue":"6","key":"7653_CR27","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.numecd.2018.02.014","volume":"28","author":"E Raschi","year":"2018","unstructured":"Raschi E, Poluzzi E, Salvo F, et al. Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems. Nutr Metab Cardiovasc Dis. 2018;28(6):533\u201342.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"14","key":"7653_CR28","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1016\/j.jacc.2017.10.054","volume":"72","author":"SM Al-Khatib","year":"2018","unstructured":"Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines and the heart rhythm society. J Am Coll Cardiol. 2018;72(14):e91\u2013220.","journal-title":"J Am Coll Cardiol"},{"key":"7653_CR29","unstructured":"Boehringer Ingelheim. Press releases. https:\/\/www.boehringer-ingelheim.com\/us\/index.php\/press-releases\/fda-approves-new-treatment-option-t2d-children-10-and-older. Accessed 1 Mar 2024."},{"issue":"21","key":"7653_CR30","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"15","key":"7653_CR31","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"key":"7653_CR32","doi-asserted-by":"crossref","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in patients with chronic kidney disease.\u00a0N Engl J Med. 2023;388(2):117\u2013127.","DOI":"10.1056\/NEJMoa2204233"},{"issue":"10","key":"7653_CR33","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/j.hrthm.2018.06.017","volume":"15","author":"MJ Junttila","year":"2018","unstructured":"Junttila MJ, Kiviniemi AM, Lepoj\u00e4rvi ES, et al. Type 2 diabetes and coronary artery disease: preserved ejection fraction and sudden cardiac death. Heart Rhythm. 2018;15(10):1450\u20136.","journal-title":"Heart Rhythm"},{"issue":"4","key":"7653_CR34","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00380-006-0962-9","volume":"22","author":"MR Movahed","year":"2007","unstructured":"Movahed MR, Hashemzadeh M, Jamal M. Increased prevalence of ventricular fibrillation in patients with type 2 diabetes mellitus. Heart Vessels. 2007;22(4):251\u20133.","journal-title":"Heart Vessels"},{"key":"7653_CR35","doi-asserted-by":"crossref","unstructured":"Xu B, Kang B, Zhou J. Sodium glucose cotransporter 2 inhibitors with cardiac arrhythmias in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized placebo-controlled trials. Clin Res Cardiol. 2024;113(6):910\u2013923.","DOI":"10.1007\/s00392-024-02386-6"},{"issue":"1","key":"7653_CR36","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12933-024-02137-x","volume":"23","author":"J Liao","year":"2024","unstructured":"Liao J, Ebrahimi R, Ling Z, et al. Effect of SGLT-2 inhibitors on arrhythmia events: insight from an updated secondary analysis of > 80,000 patients (the SGLT2i-arrhythmias and sudden cardiac death). Cardiovasc Diabetol. 2024;23(1):78.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"7653_CR37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12933-020-01048-x","volume":"19","author":"HY Chen","year":"2020","unstructured":"Chen HY, Huang JY, Siao WZ, Jong GP. The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study. Cardiovasc Diabetol. 2020;19(1):73.","journal-title":"Cardiovasc Diabetol"},{"key":"7653_CR38","doi-asserted-by":"publisher","first-page":"1012220","DOI":"10.3389\/fcvm.2022.1012220","volume":"9","author":"A Cesaro","year":"2022","unstructured":"Cesaro A, Gragnano F, Paolisso P, et al. In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: insights from the SGLT2-I AMI PROTECT study. Front Cardiovasc Med. 2022;9:1012220.","journal-title":"Front Cardiovasc Med"},{"issue":"12","key":"7653_CR39","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1007\/s00380-023-02298-x","volume":"38","author":"M Nakase","year":"2023","unstructured":"Nakase M, Yahagi K, Horiuchi Y, et al. Effect of dapagliflozin on ventricular repolarization in patients with heart failure with reduced ejection fraction. Heart Vessels. 2023;38(12):1414\u201321.","journal-title":"Heart Vessels"},{"issue":"7","key":"7653_CR40","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.tcm.2022.04.003","volume":"33","author":"AA Manolis","year":"2023","unstructured":"Manolis AA, Manolis TA, Melita H, Manolis AS. Sodium-glucose cotransporter type 2 inhibitors and cardiac arrhythmias. Trends Cardiovasc Med. 2023;33(7):418\u201328.","journal-title":"Trends Cardiovasc Med"},{"key":"7653_CR41","doi-asserted-by":"publisher","first-page":"1159953","DOI":"10.3389\/fcvm.2023.1159953","volume":"10","author":"T Sato","year":"2023","unstructured":"Sato T, Kouzu H, Yano T, Sakuma I, Furuhashi M, Tohse N. Potential favorable action of sodium-glucose cotransporter-2 inhibitors on sudden cardiac death: a brief overview. Front Cardiovasc Med. 2023;10:1159953.","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"7653_CR42","doi-asserted-by":"publisher","first-page":"H341","DOI":"10.1152\/ajpheart.00391.2022","volume":"324","author":"T Kadosaka","year":"2023","unstructured":"Kadosaka T, Watanabe M, Natsui H, et al. Empagliflozin attenuates arrhythmogenesis in diabetic cardiomyopathy by normalizing intracellular Ca2+ handling in ventricular cardiomyocytes. Am J Physiol Heart Circ Physiol. 2023;324(3):H341\u201354.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"7653_CR43","doi-asserted-by":"publisher","first-page":"H418","DOI":"10.1152\/ajpheart.00729.2023","volume":"326","author":"J Sauer","year":"2024","unstructured":"Sauer J, Marksteiner J, Lilliu E, et al. Empagliflozin treatment rescues abnormally reduced Na+ currents in ventricular cardiomyocytes from dystrophin-deficient mdx mice. Am J Physiol Heart Circ Physiol. 2024;326(2):H418\u201325.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"7653_CR44","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12933-021-01392-6","volume":"20","author":"Z Hu","year":"2021","unstructured":"Hu Z, Ju F, Du L, Abbott GW. Empagliflozin protects the heart against ischemia\/reperfusion-induced sudden cardiac death. Cardiovasc Diabetol. 2021;20(1):199.","journal-title":"Cardiovasc Diabetol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07653-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-024-07653-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07653-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:01:03Z","timestamp":1766127663000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-024-07653-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["7653"],"URL":"https:\/\/doi.org\/10.1007\/s10557-024-07653-2","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,4]]},"assertion":[{"value":"14 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All authors declare that they have no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}